Genus PLC (GNS) is a publicly traded biotechnology business based in the UK which employs around 3,500 staff. Genus is listed on the London Stock Exchange (LSE) and traded in sterling. Its current price of 1736p is 4.5% down on its price a month ago (1817p).
Both exchange rates and share prices fluctuate in real time, so the costs estimated here should be considered as a guide only. They don't factor in spreads, which can be hard to pin down. Always refer to the platform itself for availability and pricing.
Quantity of shares
| Platform | Finder score | Account fee | Min. initial deposit | Trade cost | Link |
|---|---|---|---|---|---|
 |
4.39 ★★★★★ |
£0 | $100 | £1,753.40 |
Go to siteCapital at risk
|
 |
3.75 ★★★★★ |
0.12% per year | £0 | £1,752.68 |
Go to siteCapital at risk
|
 |
4.3 ★★★★★ |
£0 | £0 | £1,744.68 |
Go to siteCapital at risk
|
 |
4.2 ★★★★★ |
£0 | £1 | £1,756.63 |
Go to siteCapital at risk
|
 |
4.34 ★★★★★ |
0% - 0.25% | £100 | £1,744.68 |
Go to siteCapital at risk
|
 |
4.1 ★★★★★ |
£0 | £0 | N/A |
Read reviewCapital at risk
|
 |
4.4 ★★★★★ |
£0 | £0 | £1,744.68 |
Read reviewCapital at risk
|
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Buying shares in just one company is generally considered a riskier bet than investing in a range of investments - AKA a "diversified portfolio". Experts generally recommend holding a mix of investments in specific assets and funds. Funds are ready-made portfolios of multiple companies' shares (potentially including Genus), and the idea is that drops in the value of one constituent company's share price might be offset by rises in others.
Genus is a major part of the London stock exchange, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).
| Icon | Fund | 5-year performance | 1-year performance (to October 2023) | Link to invest |
|---|---|---|---|---|
 | Vanguard FTSE 250 UCITS ETF Distributing (VMID) | 1.77% | -0.53% | Capital at risk |
 | Invesco FTSE 250 UCITS ETF (S250) | 1.20% | -0.66% | Capital at risk |
 | Xtrackers FTSE 250 UCITS ETF 1D (XMCX) | 1.08% | -0.67% | Capital at risk |
 | HSBC FTSE 250 UCITS ETF GBP (HMCX) | 0.22% | -0.74% | Capital at risk |
 | iShares FTSE 250 UCITS ETF (MIDD) | 0.16% | -0.78% | Invest with eToroCapital at risk |
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Genus's shares have ranged in value from as little as 1469.6812 up to 2754.1703. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Genus's is 0.312. This would suggest that Genus's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of 1736
| 1 week (2024-04-18) | 1.05% |
|---|---|
| 1 month (2024-03-25) | -4.46% |
| 3 months (2024-01-25) | -25.88% |
| 6 months (2023-10-25) | -16.05% |
| 1 year (2023-04-25) | -36.04% |
| 2 years (2022-04-25) | -33.99% |
| 3 years (2021-04-25) | -66.55% |
| 5 years (2019-04-25) | -25.11% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Genus P/E ratio, PEG ratio and EBITDA
Genus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Genus shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United Kingdom stock market as of 09 November, 2023 (10). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Genus's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Genus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £70.1 million.
The EBITDA is a measure of a Genus's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Sign up for weekly expert share tips
Join 100,000 subscribers who are notified about expert share tips. Plus a chance to win £800!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Canopy Growth? We explain how and compare a range of providers that can give you access to many brands, including Canopy Growth.
Ever wondered how to buy shares in Green Thumb Industries? We explain how and compare a range of providers that can give you access to many brands, including Green Thumb Industries.
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
Ever wondered how to buy shares in Genesis Healthcare? We explain how and compare a range of providers that can give you access to many brands, including Genesis Healthcare.
Ever wondered how to buy shares in Allergy Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Allergy Therapeutics.
Ever wondered how to buy shares in 4D pharma? We explain how and compare a range of providers that can give you access to many brands, including 4D pharma.
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
Thinking about buying shares in Evgen Pharma? We explain how to do it and compare a range of providers who will give you access to global markets.
Ever wondered how to buy shares in Intuitive Surgical? We explain how and compare a range of providers that can give you access to many brands, including Intuitive Surgical.
Ever wondered how to buy shares in Stryker? We explain how and compare a range of providers that can give you access to many brands, including Stryker.